Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CCEL 
CryoCell International Inc (CCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: CCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.5
1 Year Target Price $8.5
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22.98% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.04M USD | Price to earnings Ratio - | 1Y Target Price 8.5 |
Price to earnings Ratio - | 1Y Target Price 8.5 | ||
Volume (30-day avg) 1 | Beta 0.75 | 52 Weeks Range 4.09 - 8.62 | Updated Date 10/24/2025 |
52 Weeks Range 4.09 - 8.62 | Updated Date 10/24/2025 | ||
Dividends yield (FY) 14.64% | Basic EPS (TTM) -0.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-15 | When - | Estimate -0.04 | Actual 0.09 |
Profitability
Profit Margin -1.49% | Operating Margin (TTM) 24.29% |
Management Effectiveness
Return on Assets (TTM) 4.29% | Return on Equity (TTM) 129.2% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 47857529 | Price to Sales(TTM) 1.1 |
Enterprise Value 47857529 | Price to Sales(TTM) 1.1 | ||
Enterprise Value to Revenue 1.5 | Enterprise Value to EBITDA 8.98 | Shares Outstanding 8055150 | Shares Floating 4227262 |
Shares Outstanding 8055150 | Shares Floating 4227262 | ||
Percent Insiders 41.73 | Percent Institutions 12.37 |
Upturn AI SWOT
CryoCell International Inc
Company Overview
History and Background
Cryo-Cell International, Inc. was founded in 1989. It was one of the first private cord blood banks. The company has focused on umbilical cord blood and tissue cryopreservation.
Core Business Areas
- Cord Blood Banking: Cryo-Cell International's primary business is the cryopreservation of umbilical cord blood, which is a rich source of hematopoietic stem cells used in transplants and regenerative medicine.
- Cord Tissue Banking: The company also offers cryopreservation of umbilical cord tissue, which contains mesenchymal stem cells with potential therapeutic applications.
- Family Health Storage: Offers services like newborn screening and genetic testing and storing products for their customers.
Leadership and Structure
Cryo-Cell International is led by a board of directors and executive management team. Details on specific individuals and organizational structure are publicly available in SEC filings and on their investor relations page.
Top Products and Market Share
Key Offerings
- Cord Blood Cryopreservation: The company's core service is the long-term storage of umbilical cord blood. Details of the market share or revenue related specifically to this product is not readily available to the public. Key competitors include Americord Registry, ViaCord, and Cord Blood Registry (CBR). It is a crowded market.
- Cord Tissue Cryopreservation: Cryo-Cell also offers the option to preserve umbilical cord tissue. Details of the market share or revenue related specifically to this product is not readily available to the public. Key competitors include Americord Registry, ViaCord, and Cord Blood Registry (CBR). It is a crowded market.
Market Dynamics
Industry Overview
The stem cell banking industry is growing, driven by increasing awareness of the potential therapeutic uses of stem cells. Factors influencing the market include advancements in regenerative medicine, rising prevalence of diseases treatable with stem cell transplants, and increasing disposable income.
Positioning
Cryo-Cell International is one of the established players in the private cord blood banking industry. Competitive advantages may include brand recognition, longevity in the market, and proprietary technologies or processes.
Total Addressable Market (TAM)
The global cord blood banking market is expected to reach billions of dollars. Cryo-Cell International is positioned to capture a share of this TAM through its established services and marketing efforts. The 2024 TAM is expected to be around $4.5 billion USD.
Upturn SWOT Analysis
Strengths
- Early mover advantage
- Established brand reputation
- Proprietary technologies/processes
- Long-term customer relationships
Weaknesses
- High marketing costs
- Reliance on consumer awareness and acceptance
- Competition from larger players
- Regulatory uncertainties
Opportunities
- Expansion into new geographic markets
- Development of new stem cell-based therapies
- Partnerships with hospitals and healthcare providers
- Increasing awareness of stem cell benefits
Threats
- Intense competition
- Technological advancements rendering current methods obsolete
- Changing regulations
- Economic downturns affecting consumer spending
- Ethical concerns
Competitors and Market Share
Key Competitors
- VIAC
- AMCX
- LIFE
Competitive Landscape
Cryo-Cell International operates in a competitive market. Its advantages may lie in its brand recognition and established infrastructure. Disadvantages could include smaller scale compared to some larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth can be assessed by analyzing the company's revenue and profitability trends over the past several years as reported in their SEC filings.
Future Projections: Future growth projections are available through analyst estimates from reputable financial news sources.
Recent Initiatives: Review press releases and investor presentations for recent strategic initiatives undertaken by the company.
Summary
Cryo-Cell International is a longstanding player in the cord blood and tissue banking industry. Its strengths lie in its established brand and early mover advantage. However, it faces intense competition and must continuously innovate to stay relevant. Successful expansion into new markets and development of novel therapies are crucial for sustained growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Financial News Sources
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CryoCell International Inc
Exchange NYSE MKT | Headquaters Oldsmar, FL, United States | ||
IPO Launch date 1997-01-21 | Chairman & Co-CEO Mr. David I. Portnoy | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 82 | Website https://www.cryo-cell.com |
Full time employees 82 | Website https://www.cryo-cell.com | ||
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.